plx-005/04

Size: px

Start display at page:

Download "plx-005/04"

翁曰杨
9 years ago
Views:

2 (HCV) (HCC)

3 3 2 HCV HCV Flaviviridae) RNA 6 HCV ( 1a 2b 3c ) 1 HCV 70% HCV quasispecies HCV HCV ORF 10 NS NS3 / NS5B RNA RNA HCV HCV 100 5min 60 10h WHO HCV 3% 1.7 HCV 3.5 -HCV 3.2% -HCV 3.6% 2.9% 2.5% 2.7% 3.2% 3.3% 3.8% 4.6% -HCV 1 2.0% % HCV 1b 2a 1b 1a 2b 3b HCV (1) HCV -HCV -HCV -HCV HCV RNA HCV (2) HCV 60%-90% HCV HCV 2 HCV HCV HIV HCV 3 -HCV HCV 2% HCV RNA 4%-7% HIV 20% HCV HCV HCV

4 5 4 HCV 1-3 HCV RNA HCV 50%-70% -HCV 3 90% -HCV HCV 6 50%-85% 20 2%-4% 20%-30% 10%-15% 40 HCV HCV 40 HIV HBV) 50g/ NASH HCV HCC 30 1%-3% HCC 1%-7% HCC HCC HCC HCC 10 80% 10 25% IFN α ( ) HCC HCV -HCV (ALT) HCV HCV HCV RNA

5 1 HCV ALT -HCV HCV RNA HCV RNA ALT ALT HCV RNA HCV HCV HIV HBV HCV 3 (Sjogren syndrome) 7

6 B -HCV EIA 99% 4 HCC HCV RIBA HCC 5 HCV HBV HIV 6 HCV HCV HCV /ml HCV RNA /ml HCV RNA HCV RNA 1 HCV RNA -HCV HCV HCV RNA HCV RNA 98% HCV ALT AST HCV ALT AST HCV 2 HCV RNA qpcr DNA bdna ALT AST PCR HCV RNA HCV RNA PCR Cobas V2.0 SuperQuant LC HCV RNA bdna Versant HCV RNA PCR SFDA 30%ALT 40% 2 HCV RNA /ml IU/ml Cobas ALT V2.0 IU/ml SuperQuant /ml IU/ml=0.854 /ml HCV -HCV -HCV -HCV RNA HCV RNA HCV RNA EIA HCV 8 9

HCV RNA HCV RNA PCR Cobas V2.0 SuperQuant LC HCV RNA bdna Versant HCV RNA 2.0 3.

7 HCV HCV RNA Simmonds 1-6 HCV RNA (1) (2) (3) (4) 10

8 HCV HCC (G 2) (S 2) (2) ALT IFNα HCV IFNα IFN S2 S3 PEG α PEG-IFNα IFNα S0 PEG IFNα S1 3-6 (3) ALT 1 IFNα 9µg IFNα 3MU IFNα ALT PEG-IFNα IFNα IFNα PEG-IFNα-2a ALT PEG-IFNα-2a 180µg PEG-IFNα-2b 1.5µg/kg 1 ALT 48 SVR 54%-56% IFNα 3MU 3 48 SVR 44%-47% PEG-IFNα-2a IFNα 48 SVR PEG-IFNα-2a 180µg 24 SVR 41.5% % 1 IFNα 3MU mg/d 2 (1) ALT AST 3 (1) Child-Pugh A 25%-39% 12%-19% HCC (2) 66.7% IFNα 4 HCV HCC HCV IFNα HCV RNA 1 IFNα HCV RNA

5µg/kg 1 ALT 48 SVR 54%-56% IFNα 3MU 3 48 SVR 44%-47% PEG-IFNα-2a IFNα 48 SVR PEG-IFNα-2a 180µg 24 SVR 41.5% 1 35.

9 IFNα HCV IFNα 2 HCV HCC 3. HBV HIV HBV HCC HCV RNA /HBV DNA HCV IFNα HCV HBV DNA HBV / <1.0X10 9 /L <50X10 9 /L Hb<100 g/l HIV HCV Hb<80 g/l CD4 + 6 HAART HCV HAART S2 S3 HCV HIV CD4 + < /L HIV HCV 4 1 ALT AST 2 (1) EVR 12 IFNα HCV RNA 2 (Log) EVR SVR EVR SVR EVR SVR (2) ETVR 14 15

10 HCV RNA ( ) (3) SVR 48 (3) HCV RNA 24 HCV RNA ( HCV RNA ) (4) (NR) EVR ETVR SVR (5) (relapse) HCV RNA ( ) HCV RNA (6) breakthrough HCV RNA HCV RNA 3. IFNα IFNα PEG-IFN 3. HCV RNA 1 HCV RNA < /ml 1 PEG-IFNα PEG-IFNα-2a 180µg 1 800mg/d 24 2 IFNα 3MU 3 SVR (1) HCV 2 3 (2) < 2x10 6 /ml (3) <40 (4) (5) HCV (6) (7) (8) (9) HBV HIV (10) PEG-IFNα IFNα 3-5MU mg/d mg/d IFNα PEG-IFN : (1) PEG-IFNα-2b 1.0 _ 1.5µg/kg PEG-IFNα-2a 180µg 1 48 SVR (2) IFNα IFNα 3-5MU 15-30d 3 HCV RNA (1 1 ) HCV RNA (3) >85kg 1 200mg/d 65-85kg 000mg/d <65kg 800mg/d HCV RNA 1 ( )HCV RNA 2X10 6 /ml >10.6mg/kg 1 PEG-IFNα PEG-IFNα-2a 180µg 1 IFNα PEG-IFNα-2a 1 000mg/d 12 HCV RNA (1) SVR 47% 60% HCV RNA <2 (2) HCV RNA IFNα IFNα PEG-IFNα-2a 16 17

3-5MU 1 1 000mg/d 48 800-1 000mg/d 24-48 3. IFNα PEG-IFN : (1) PEG-IFNα-2b 1.0 _ 1.

11 SVR 12%-15% 34%-40% 5 IFNα PEG-IFNα-2a 1 IFNα Hb 100g/L Hb 80g/L IFNα IFNα /L < /L IFNα /L < /L 1. (G-CSF) 1 (GM-CSF) ALT 6 IFNα 1 HCV ALT IFNα 3. 3 HCV RNA IFNα 6 HCV RNA 4 IFNα

50 10 9 /L <30 10 9 /L 1. (G-CSF) 1 (GM-CSF) 1 6 3 1 3 2.

12 1 Alberti A, Benvegnu L, Management of Hpatitis C. J Hepatol, 2003, 38(suppl.1):S1014-S118. Booth JCL, 0' Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut, 2001, 49(suppl I):il-i suppl.1):s135-s ALT 5 2 ALT 24 1 Viral Hepat, 2003, 10: ALT 6 Pharmacol Ther, 2003, 18: AFP B CT MRI HCC randomised trials. BMJ, 2001, 323: AFP X 2002, 36:(5 Suppl.1) : S Camma C, Bruno S, Schepis F, et al. Retreatment with Interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002, 51: Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review. Hepatology, 2002, 36(5 Di Ciommo V, Russo P, Rava L, et al. Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis. J Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of National Institute of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology, Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther, 2001, 15: Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology, 2000, 32: ,. : ( ), 12,, 13,, 14, Tracy L, 15 2,, 1997:60-71.,.., 1997, 15:71-75.,. HCV., 2004, 12:72-75,.., 2001, 22: , 2000, 8:

BMJ, 2001, 323:1151-1155. 50 AFP 8 1-2 X 2002, 36:(5 Suppl.1) : S3-20. 9 Camma C, Bruno S, Schepis F, et al.

丙型肝炎治疗进展及临床-实验室沟通（南月敏） [兼容模式]

丙型肝炎治疗进展及临床-实验室沟通（南月敏） [兼容模式] 丙型肝炎诊疗进展实验室检查是临床诊疗的基石南月敏教授博士生导师河北省医学会肝病学分会河北医科大学第三医院中西医结合肝病科全球 HCV 感染状况 1.7 亿人感染 HCV(3%) 美洲 1310 万 (1.7%) 欧洲 890 万 (1.03%) 非洲 3190